It’s not everyday that you come across a company that offers such favorable risk and reward traits like Belgravia Capital International Inc (CSE: BLGV), formerly IC Potash Corp.
Belgravia is developing organic cannabis fertilizers and products with the goal of maximizing the health effects and yield of crops in the expanding marijuana industry. But what makes it special is that it has done an amazing job of diversifying its revenues during its research phase, substantially lowering its risk.
Under its wholly-owned subsidiary ICP Organics, the company plans to build a diversified portfolio in dispensary operations and commercial-scale cannabis cultivation, product formulation and pharmaceutical-grade testing; just in time for the anticipated legalization of marijuana in Canada.
Research has already begun, and Belgravia expects to complete the research phase in 2018, after which it will focus on selling its products to major cannabis producers in the U.S. and Canada.
The planned products are unique in that they will be designed to restore the soil’s natural ecosystem, energizing the soil microbial processes necessary for conversion of phosphorous, potassium, sulphur, and nitrogen into forms that can be absorbed and used by plants, leading to healthier and larger crops.
The reward potential is very high in the research stage since the shares are cheap, but isn’t it also very risky? Yes, but Belgravia has been around for over a decade and has acquired several unrelated interests that will provide the funding needed to get from research to product to sales, thereby reducing the risk significantly. This is the beauty of Belgravia.
Belgravia has recently sold its Ochoa Project, a potash interest, and will be receiving instalments in 2018. It also will be receiving substantial royalties from a water project in New Mexico in March, 2018. Another mining interest in Argentina could be sold to provide more funds, if needed.
These diversified sources of funding will provide Belgravia with ample funds for its research stage.
But why not wait a little for the research to come along further and for purchase agreements to take place? Because by then Belgravia’s price will have already risen to reflect this added value and reduction of uncertainty, and investors who stood idly by will have missed out on the gains.
Currently, Belgravia is speaking with several major organic cannabis producers and expects a purchase agreement to be finalized in the first quarter of 2018, but the market hasn’t priced this in.
The lower-than-average current trading volume for Belgravia indicates that the market isn’t aware of this opportunity yet: The time is now.
Belgravia Capital International offers massive growth potential, with relatively minimal risk. It combines an experienced team, secure financing to get through the research stage, and a realistic vision to deliver shareholder value in a growing industry: Make sure you grow with it.